Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
Go back to Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia| ARROWHEAD RESEARCH (NASDAQ: ARWR) | Delayed: 85.60 -1.18 (1.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $86.78 | 52 Week High | $8.22 | |||
| Open | $86.84 | 52 Week Low | $3.07 | |||
| Day High | $87.50 | P/E | N/A | |||
| Day Low | $85.06 | EPS | $-1.30 | |||
| Volume | 1,825,230 | |||||
